Duong Huong, Fullbrook Shannon, Reddington Kate, Minogue Elizabeth, Barry Thomas
Nucleic Acid Diagnostics Laboratory, Microbiology, School of Natural Sciences, National University of Ireland Galway, Galway, Ireland; and.
Microbial Diagnostics Research Laboratory, Microbiology, School of Natural Sciences, National University of Ireland Galway, Galway, Ireland.
PDA J Pharm Sci Technol. 2023 Jul-Aug;77(4):296-310. doi: 10.5731/pdajpst.2021.012728. Epub 2023 Feb 23.
In the wake of a series of outbreaks of finished pharmaceutical product-related complex (Bcc) human infections worldwide, the United States Food and Drug Administration (FDA) in 2017, and subsequently in 2021, issued advisory notifications to the pharmaceutical industry for stringent Bcc testing requirements for pharmaceutical manufacturing processes and for finished pharmaceutical products prior to release to the marketplace. The advisory notifications highlight non-sterile aqueous finished pharmaceutical products as being a major culprit associated with many of these human infection events. As such, there has been a significant number of Bcc-contaminated finished product recalls resulting in company revenue losses, delayed finished product release, finished product shortages for patients, and manufacturing plant shutdowns coupled with company reputational damage. With many of the finished product recall events, pharmaceutical grade water and/or manufacturing facility water distribution systems were identified as the primary origin source of Bcc contamination. Testing and monitoring regimes currently employed to identify Bcc contamination of water associated with pharmaceutical manufacturing are often limited by costly, laborious, lengthy, and nonspecific traditional microbial culture-based methodologies. Presently FDA approved, European Conformity (CE) marked, and International Organization for Standardization (ISO) standard microbial culture-independent rapid, quantitative, specific, and sensitive nucleic acid diagnostics (NAD) methodologies are now gaining greater widespread acceptance in their routine usage in testing laboratories. Here we present the development of a rapid (<4 hours from sample in to result out) single test culture-independent Bcc NAD method, incorporating a quantitative real-time polymerase chain reaction (qPCR) assay. This method can be used for the detection and simultaneous identification of all 24 Bcc species currently assigned, directly from water samples. This culture-independent Bcc NAD method is validated to the testing method equivalent of the ISO/TS 12869:2019 standard, which is a widely used rapid culture-independent NAD method for detecting Gram-negative species in water.
在全球范围内发生了一系列与成品药品相关的复杂性(Bcc)人类感染疫情之后,美国食品药品监督管理局(FDA)于2017年,随后在2021年,向制药行业发布了咨询通知,要求对药品生产工艺和成品药品在投放市场之前进行严格的Bcc检测。这些咨询通知强调非无菌水性成品药品是与许多此类人类感染事件相关的主要罪魁祸首。因此,出现了大量受Bcc污染的成品召回事件,导致公司收入损失、成品发布延迟、患者成品短缺以及生产工厂关闭,同时公司声誉受损。在许多成品召回事件中,制药级水和/或生产设施的水分配系统被确定为Bcc污染的主要源头。目前用于识别与药品生产相关的水的Bcc污染的检测和监测方法,往往受到基于传统微生物培养的方法成本高、费力、耗时且非特异性的限制。目前,FDA批准的、欧洲合格认证(CE)标志的以及国际标准化组织(ISO)标准的非依赖微生物培养的快速、定量、特异性和灵敏的核酸诊断(NAD)方法,在检测实验室的常规使用中越来越受到广泛认可。在此,我们展示了一种快速(从进样到出结果<4小时)的单测试非依赖培养的Bcc NAD方法的开发,该方法采用了定量实时聚合酶链反应(qPCR)检测。这种方法可直接用于从水样中检测和同时鉴定目前指定的所有24种Bcc菌种。这种非依赖培养的Bcc NAD方法已按照等同于ISO/TS 12869:2019标准的测试方法进行了验证,该标准是一种广泛用于检测水中革兰氏阴性菌的快速非依赖培养的NAD方法。